Hiroyuki Suzuki

This study identifies CLSTN3B as a driver of MASLD by promoting LD biogenesis and altering lipid partitioning between LDs and mitochondria, leading to mitochondrial dysfunction and oxidative stress.

This study shows that CLSTN3B promotes lipid droplet maturation in hepatocytes and that its deletion reduces steatohepatitis in mice, with a positive correlation between CLSTN3B expression and MASLD severity in humans.

The paper examines the impact of S-1 biomarkers on aging and prognosis in elderly lung cancer patients undergoing adjuvant S-1 chemotherapy, finding that high EGFR and low TS expression correlate with better survival outcomes.